Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biol Reprod ; 64(3): 865-70, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11207202

RESUMO

The presence of binding sites for formyl-methionyl-leucyl-phenylalanine (fMLP), its effect on prostaglandin E (PGE) release, and the signal transduction pathway activated by the peptide were investigated in human amnion-derived WISH cells. Our results demonstrate that specific binding sites for fMLP are present on WISH cells and that the peptide induces a significant increase of prostaglandin (PG)E2 release. The kinetic properties of binding are similar to those previously found in amnion tissue prior to the onset of labor, i.e., only one population of binding sites with low affinity for the peptide is present. Binding of 3H-fMLP in WISH cells is inhibited by N-t-butoxycarbonyl-methionyl-leucyl-phenylalanine, an fMLP receptor antagonist, with an IC50 value very close to that shown by nonlaboring amnion. The fMLP-induced PGE2 output is inhibited by indomethacin, quinacrine, and U-73122, inhibitors of cyclooxygenase, phospholipase A2, and phospholipase C, respectively. As regards the transduction pathway activated by fMLP, we demonstrate that phospholipase C activation, followed by an increase of intracellular calcium concentration ([Ca2+]i), is involved in response to the peptide. Our results add further evidence to the role of proinflammatory agents in the determination of labor. Furthermore, because WISH cells appear to behave like nonlaboring amnion tissue, they represent the ideal candidate for in vitro investigation of the events triggering the mechanism of delivery.


Assuntos
Âmnio/efeitos dos fármacos , Cálcio/metabolismo , Dinoprostona/metabolismo , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Fosfolipases Tipo C/fisiologia , Âmnio/enzimologia , Âmnio/metabolismo , Sítios de Ligação , Cálcio/fisiologia , Linhagem Celular , Inibidores de Ciclo-Oxigenase/farmacologia , Dinoprostona/biossíntese , Inibidores Enzimáticos/farmacologia , Estrenos/farmacologia , Humanos , Indometacina/farmacologia , Microscopia Confocal , N-Formilmetionina Leucil-Fenilalanina/metabolismo , Oligopeptídeos/farmacologia , Pirrolidinonas/farmacologia , Quinacrina/farmacologia , Radioimunoensaio , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Fosfolipases Tipo C/antagonistas & inibidores
2.
Br J Haematol ; 104(2): 258-65, 1999 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10050705

RESUMO

The human leukaemic K562 cell line can be induced in vitro to undergo erythroid differentiation by a variety of chemical compounds, including haemin, butyric acid, 5-azacytidine and cytosine arabinoside. Differentiation of K562 cells is associated with an increased expression of embryo-fetal globin genes, such as the zeta, epsilon and gamma globin genes. Therefore the K562 cell line has been proposed as a useful in vitro model system to determine the therapeutic potential of new differentiating compounds as well as to study the molecular mechanism(s) regulating changes in the expression of embryonic and fetal human globin genes. Inducers of erythroid differentiation which stimulate gamma-globin synthesis could be considered for possible use in the experimental therapy of those haematological diseases associated with a failure in the expression of adult beta-globin genes. In this paper we demonstrated that the G + C selective DNA-binding drugs chromomycin and mithramycin were powerful inducers of erythroid differentiation of K562 cells. Erythroid differentiation was associated with an increase in the accumulation of (a) Hb Gower 1 and Hb Portland and (b) gamma-globin mRNA.


Assuntos
Cromomicinas/farmacologia , Células Precursoras Eritroides/patologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Inibidores da Síntese de Ácido Nucleico/farmacologia , Plicamicina/farmacologia , Sequência de Bases , Northern Blotting , Diferenciação Celular/efeitos dos fármacos , Cromomicinas/metabolismo , Pegada de DNA , Desoxirribonuclease I/metabolismo , Globinas/metabolismo , Hemoglobinas/metabolismo , Humanos , Células K562 , Leucemia Mielogênica Crônica BCR-ABL Positiva/metabolismo , Dados de Sequência Molecular , Plicamicina/metabolismo , Reação em Cadeia da Polimerase/métodos
3.
Haematologica ; 82(4): 395-401, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9299849

RESUMO

BACKGROUND AND OBJECTIVE: Human leukemic K562 cells are able to undergo erythroid differentiation in vitro when cultured with a variety of inducers, leading to increased expression of embryo-fetal globin genes such as the zita, epsilon and gamma-globin genes. Therefore the K562 cell line has been proposed as a very useful in vitro model system for determining the therapeutical potential of new differentiating compounds as well as for studying the molecular mechanism(s) that regulate changes in the expression of embryonic and fetal human globin genes. In this study we explored whether nucleoside triphosphates and related compounds are able to induce differentiation of K562 cells. METHODS: K562 cell differentiation was studied using the benzidine test; hemoglobins were characterized by cellulose acetate gel electrophoresis and mRNA accumulation was investigated by Northern blot analysis. RESULTS: The main conclusion of this paper is that guanine, guanosine and guanine ribonucleotides are effective inducers of K562 cell differentiation. Expression of both Hb Portland and Hb Gower 1 is increased in GTP-induced K562 cells. This increase is associated with greater gamma-globin mRNA accumulation. By contrast, ATP, CTP and UTP are not able to induce erythroid differentiation. INTERPRETATION AND CONCLUSIONS: These findings suggest that guanine, guanosine and guanine ribonucleotides are inducers of erythroid differentiation of K562 cells. This is of some relevance since differentiating compounds have been proposed as antitumor agents. In addition, inducers of erythroid differentiation that stimulate gamma-globin synthesis might be considered in the experimental therapy of hematological diseases associated with a failure in the expression of adult beta-globin genes.


Assuntos
Eritrócitos/patologia , Nucleotídeos de Guanina/farmacologia , Guanina/farmacologia , Guanosina/farmacologia , Leucemia/patologia , Diferenciação Celular/efeitos dos fármacos , Humanos , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...